CSF concentrations of placental growth factor (PlGF) were measured in the discovery cohort including patients with FTD (<i>n</i> = 27), Alzheimer disease (AD) dementia (<i>n</i> = 75), DLB or PDD (<i>n</i> = 47), subcortical vascular dementia (VaD, <i>n</i> = 33), mild cognitive impairment that later converted to AD (MCI-AD, <i>n</i> = 34), stable MCI (sMCI, <i>n</i> = 62), and 50 cognitively healthy controls from the Swedish BioFINDER study.